NCT05055518 - APL-102 Capsule in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

October 31, 2028

Study Completion Date

December 31, 2028

Conditions

Advanced Solid Tumor

Interventions

DRUG

APL-102 Capsules

"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."

Trial Locations (1)

Unknown

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing